FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2783057186> ?p ?o ?g. }

• W2783057186 endingPage "221" @default.
• W2783057186 startingPage "220" @default.
• W2783057186 abstract "INTRODUCTION: Immunotherapies are a relatively new innovative class of drug that have garnered excitement in the fight against cancer. In 2011, the immunotherapy drug, ipilimumab, was approved. Since then, four additional drugs have gained approval. This analysis evaluates the initial reception of immunotherapies by Health Technology Assessment (HTA) agencies. METHODS: The Context Matters Data Model was used to evaluate the regulatory and HTA agency decisions surrounding the five approved immunotherapies through November 2016: atezolizumab, elotuzumab, ipilimumab, nivolumab, and pembrolizumab. Thirty-three labels from Australia, Canada, Europe, and the United States, and ninety-two assessments from Agenzia Italiana del Farmaco (AIFA), Gemeinsamer Bundesausschuss (Federal Joint Committee; G-BA), Haute Autorité de Santé (French National Authority for Health; HAS), Institute for Clinical and Economic Review (ICER), Institute for Quality and Efficiency in Health Care (IQWiG), National Institute for Health and Care Excellence (NICE), Pharmaceutical Benefits Advisory Committee (PBAC), pan-Canadian Oncology Drug Review (pCODR), and Scottish Medicines Consortium (SMC) were found. Using a sample t-test and a chi-squared test, reimbursement agencies’ decisions were evaluated, and the clinical and economic factors that went into these decisions were examined. RESULTS: Of the evaluated reviews: sixty-four were for melanoma indications, fourteen were for non-small-cell lung cancer (NSCLC) indications, and seven were for kidney cancer indications. Many of the reviews did not reach any decision, but 75 percent of HTA decisions (n = 72; p = .0000) reached were positive. Elotuzumab, approved for multiple myeloma, received a positive decision from G-BA and a negative one from SMC. There was an association between different disease conditions or drugs and the rate of positive decisions. For reviews that had clinical reasons for their decisions, 72.9 percent (n = 59; p = .0000) had positive clinical rationales that were associated with positive decisions (p = .000). Economic rationales for decisions were more mixed, with only 48.4 percent (n = 31; p = .0000) receiving positive decisions. Positive economic evaluations were also associated with positive decisions (p = .000). Atezolizumab, approved only in the United States at the time of this writing, has yet to be reviewed by any of the HTA agencies. CONCLUSIONS: Immunotherapies are promising new options for the treatment of cancer. Thus far, reception by HTA agencies has generally been positive." @default.
• W2783057186 created "2018-01-26" @default.
• W2783057186 creator A5005546795 @default.
• W2783057186 creator A5010789373 @default.
• W2783057186 creator A5020530712 @default.
• W2783057186 creator A5028490559 @default.
• W2783057186 creator A5034879617 @default.
• W2783057186 creator A5036343242 @default.
• W2783057186 creator A5038393278 @default.
• W2783057186 creator A5053435841 @default.
• W2783057186 creator A5076423884 @default.
• W2783057186 creator A5082306567 @default.
• W2783057186 date "2017-01-01" @default.
• W2783057186 modified "2023-09-26" @default.
• W2783057186 title "VP157 What Is The Response To Immuno-Oncology By Health Technology Assessment Agencies?" @default.
• W2783057186 doi "https://doi.org/10.1017/s0266462317003968" @default.
• W2783057186 hasPublicationYear "2017" @default.
• W2783057186 type Work @default.
• W2783057186 sameAs 2783057186 @default.
• W2783057186 citedByCount "0" @default.
• W2783057186 crossrefType "journal-article" @default.
• W2783057186 hasAuthorship W2783057186A5005546795 @default.
• W2783057186 hasAuthorship W2783057186A5010789373 @default.
• W2783057186 hasAuthorship W2783057186A5020530712 @default.
• W2783057186 hasAuthorship W2783057186A5028490559 @default.
• W2783057186 hasAuthorship W2783057186A5034879617 @default.
• W2783057186 hasAuthorship W2783057186A5036343242 @default.
• W2783057186 hasAuthorship W2783057186A5038393278 @default.
• W2783057186 hasAuthorship W2783057186A5053435841 @default.
• W2783057186 hasAuthorship W2783057186A5076423884 @default.
• W2783057186 hasAuthorship W2783057186A5082306567 @default.
• W2783057186 hasConcept C121608353 @default.
• W2783057186 hasConcept C126322002 @default.
• W2783057186 hasConcept C143998085 @default.
• W2783057186 hasConcept C151730666 @default.
• W2783057186 hasConcept C160735492 @default.
• W2783057186 hasConcept C17744445 @default.
• W2783057186 hasConcept C199539241 @default.
• W2783057186 hasConcept C21333345 @default.
• W2783057186 hasConcept C2777701055 @default.
• W2783057186 hasConcept C2779343474 @default.
• W2783057186 hasConcept C2779703844 @default.
• W2783057186 hasConcept C2780030458 @default.
• W2783057186 hasConcept C2780057760 @default.
• W2783057186 hasConcept C2781433595 @default.
• W2783057186 hasConcept C512399662 @default.
• W2783057186 hasConcept C71924100 @default.
• W2783057186 hasConcept C86803240 @default.
• W2783057186 hasConceptScore W2783057186C121608353 @default.
• W2783057186 hasConceptScore W2783057186C126322002 @default.
• W2783057186 hasConceptScore W2783057186C143998085 @default.
• W2783057186 hasConceptScore W2783057186C151730666 @default.
• W2783057186 hasConceptScore W2783057186C160735492 @default.
• W2783057186 hasConceptScore W2783057186C17744445 @default.
• W2783057186 hasConceptScore W2783057186C199539241 @default.
• W2783057186 hasConceptScore W2783057186C21333345 @default.
• W2783057186 hasConceptScore W2783057186C2777701055 @default.
• W2783057186 hasConceptScore W2783057186C2779343474 @default.
• W2783057186 hasConceptScore W2783057186C2779703844 @default.
• W2783057186 hasConceptScore W2783057186C2780030458 @default.
• W2783057186 hasConceptScore W2783057186C2780057760 @default.
• W2783057186 hasConceptScore W2783057186C2781433595 @default.
• W2783057186 hasConceptScore W2783057186C512399662 @default.
• W2783057186 hasConceptScore W2783057186C71924100 @default.
• W2783057186 hasConceptScore W2783057186C86803240 @default.
• W2783057186 hasIssue "S1" @default.
• W2783057186 hasLocation W27830571861 @default.
• W2783057186 hasOpenAccess W2783057186 @default.
• W2783057186 hasPrimaryLocation W27830571861 @default.
• W2783057186 hasRelatedWork W2155654588 @default.
• W2783057186 hasRelatedWork W2970029117 @default.
• W2783057186 hasRelatedWork W2981883049 @default.
• W2783057186 hasRelatedWork W2998446840 @default.
• W2783057186 hasRelatedWork W3118553317 @default.
• W2783057186 hasRelatedWork W3120622126 @default.
• W2783057186 hasRelatedWork W3136608335 @default.
• W2783057186 hasRelatedWork W3185931698 @default.
• W2783057186 hasRelatedWork W4221029189 @default.
• W2783057186 hasRelatedWork W4318473990 @default.
• W2783057186 hasVolume "33" @default.
• W2783057186 isParatext "false" @default.
• W2783057186 isRetracted "false" @default.
• W2783057186 magId "2783057186" @default.
• W2783057186 workType "article" @default.